Prevalence of visceral manifestations in HHT1 and HHT2, for men and women
| Men | Women | p | ||||
|---|---|---|---|---|---|---|
| Patients with a doubtful result were not included in the analysis. Denominators varied between categories because not all patients underwent all examinations for all visceral organs. The statistical analysis was performed comparing men and women. The p values are shown, with p values after correction for multiple testing in brackets. | ||||||
| HHT1 | ||||||
| PAVM | 58/143 (40.6%) | 109/200 (54.5%) | 0.011 (pc = 0.054) | |||
| CAVM | 14/109 (12.8%) | 24/151 (15.9%) | 0.49 (NS) | |||
| PAVM + CAVM | 6/105 (5.7%) | 16/148 (10.8%) | 0.16 (NS) | |||
| HAVM | 1/56 (1.8%) | 10/88 (11.4%) | 0.035 (pc = 0.174) | |||
| GI telangiectases | 23/33 (69.7%) | 33/45 (73.3%) | NS (NS) | |||
| HHT2 | ||||||
| PAVM | 2/50 (4%) | 4/64 (6.3%) | 0.593 (NS) | |||
| CAVM | 0/28 (0%) | 1/48 (2.1%) | 0.442 (NS) | |||
| PAVM + CAVM | 0/27 (0%) | 0/40 (0%) | NS (NS) | |||
| HAVM | 2/12 (16.7%) | 11/20 (55%) | 0.033 (pc = 0.162) | |||
| GI telangiectases | 11/16 (68.8%) | 8/13 (61.5%) | NS (NS) | |||